Clinical trials: Systemic Lupus
Lupus Erythematosus, Systemic, Systemic Sclerosis
Occupational and Environmental Causes of Autoimmune Diseases
The investigators hypothesize that part of the systemic autoimmune diseases (AID) patients might prove to have an occupational or environmental disease which is potentially preventable.
- Conditions
- Lupus Erythematosus, Systemic, Systemic Sclerosis, Rheumatoid Arthritis
- Trial name
- EXIMIOUS (NCT07000903)
- Testing
- Exposure and immune profiles
- Where
- Belgium
- Volunteers
- 247 people
- Sponsor
- Université Catholique de Louvain
Juvenile Idiopathic Arthritis, Rheumatoid Arthritis
Medical Follow-up of New Cases of Polyarthritis in Children and Young Adults
Population: Juvenile idiopathic arthritis (JIA), rheumatoid arthritis (RA) and seronegative / psoriatic / undifferentiated arthritis (UA), systemic lupus erythematosus (SLE) or diffuse systemic sclerosis dSS).
- Conditions
- Juvenile Idiopathic Arthritis, Rheumatoid Arthritis, Psoriatic Arthritis, Systemic Lupus Erythematosus
- Trial name
- NCT07000916
- Where
- Belgium
- Volunteers
- 1,000 people
- Sponsor
- Université Catholique de Louvain
Systemic Lupus Erythematosus
A Phase Ib Study of QLS4131 in Subjects With Systemic Lupus Erythematosus
The goal of this open label, dose escalation phase 1b clinical trial is to investigate the safety, tolerability, pharmacokinetic, pharmacodynamics, immunogenicity and preliminary clinical efficacy of QLS4131 in subjects with…
- Trial name
- NCT07001839
- Testing
- QLS4131 for Injection.
- Volunteers
- 108 people
- Sponsor
- Qilu Pharmaceutical Co., Ltd.
Systemic Lupus Erythematous (SLE)
Autologous CD19 Car T-Cell Therapy For Severe Refractory Systemic Lupus Erythematosus (SLE)
This pilot clinical study aims to evaluate the effectiveness of Chimeric Antigen Receptor (CAR) T-cell therapy in treating severe, refractory systemic lupus erythematosus (SLE), an autoimmune disease driven by autoreactive…
- Trial name
- NCT06710717
- Testing
- CD19 CAR-T cells
- Where
- Malaysia
- Volunteers
- 5 people
- Sponsor
- National University of Malaysia
Systemic Lupus Erythematosus
Anti-CD19 CAR-NK Cells in Refractory/Relapsed Systemic Lupus Erythematosus
This study is a single-center, open-label, single-arm trial. The aim of this study is to investigate the safety and efficacy of anti-CD19 CAR-NK cells in patients with refractory/relapsed systemic lupus erythematosus.
- Trial name
- NCT06421701
- Testing
- anti-CD19 CAR-NK cells
- Where
- China
- Volunteers
- 10 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Lupus Nephritis (LN)
Atacicept in Subjects With Active Lupus Nephritis (COMPASS)
The objective of the study is to evaluate the effect of atacicept compared to placebo on changes to renal response in adult subjects with LN.
- Trial name
- COMPASS (NCT05609812)
- Testing
- Atacicept
- Where
- 33 sites in United States, Puerto Rico and 1 more
- Sponsor
- Vera Therapeutics, Inc.
Systemic Lupus Erythematosus (SLE), Idiopathic Inflammatory Myopathy (IIM)
A Study of OL-108 in Relapsed/Refractory Autoimmune Diseases
This study aims to characterize the safety, tolerability, pharmacokinetics, and preliminary efficacy of OL-108 in relapsed/refractory autoimmune diseases.
- Conditions
- Systemic Lupus Erythematosus (SLE), Idiopathic Inflammatory Myopathy (IIM), Systemic Sclerosis (SSc), ANCA Associated Vasculitis (AAV)
- Trial name
- NCT06980597
- Testing
- OL-108
- Where
- 2 sites in China
- Volunteers
- 44 people
- Sponsor
- Beijing GoBroad Hospital
Systemic Lupus Erythematosus, Autoimmune Hemolytic Anemia
UCAR T-cell Therapy Targeting CD19/ BCMA in Patients With Relapse/ Refractory Autoimmune Diseases
This is an investigator-initiated trial to evaluate the safety and efficacy of universal allogeneic anti-CD19/BCMA CAR T-cells in With Relapse/Refractory Autoimmune Diseases.
- Conditions
- Systemic Lupus Erythematosus, Autoimmune Hemolytic Anemia, Myasthenia Gravis, Systemic Sclerosis
- Trial name
- NCT06978738
- Testing
- universal allogeneic anti-CD19/BCMA CAR T-cells
- Where
- China
- Volunteers
- 18 people
- Sponsor
- Changzhou No.2 People's Hospital
Lupus Nephritis
Study of Safety, Efficacy and Tolerability of Secukinumab Versus Placebo, in Combination With SoC Therapy, in Patients With Active Lupus Nephritis
This was a pivotal, randomized, double-blind, placebo-controlled trial evaluating at Week 52 the efficacy and safety of secukinumab versus placebo in patients with active lupus nephritis (ISN/RPS Class III or IV, with or without…
- Trial name
- SELUNE (NCT04181762)
- Testing
- secukinumab
- Where
- 105 sites in United States, Argentina and 32 more
- Volunteers
- 275 people
- Sponsor
- Novartis Pharmaceuticals
Systemic Lupus Erythematosus
Efficacy and Safety of Belimumab in SLE Patients
Systemic lupus erythematosus (SLE) is a chronic inflammatory systemic autoimmune disease. Recurrent relapses of disease and development of long-term organ damage are two key unsolved clinical problems.
- Trial name
- NCT04515719
- Testing
- Belimumab
- Where
- China
- Volunteers
- 231 people
- Sponsor
- RenJi Hospital
Systemic Lupus Erythematosus, Rheumatoid Arthritis
Early Clinical Study of UTAA91 Injection for the Treatment of Relapsed/Refractory Autoimmune Diseases
This clinical trial is designed as a single - arm, open - label, single - center, investigator - initiated early - phase clinical study.
- Conditions
- Systemic Lupus Erythematosus, Rheumatoid Arthritis, Dry Syndrome, Idiopathic Inflammatory Myopathies
- Trial name
- NCT06970951
- Testing
- UTAA91 injection
- Where
- China
- Volunteers
- 15 people
- Sponsor
- PersonGen BioTherapeutics (Suzhou) Co., Ltd.
SLE (Systemic Lupus), CMV
Efficacy and Safety of Low-dose IL-2 in SLE Patients With CMV Viremia
This clinical trial will assess the efficacy and safety of low-dose interleukin-2 (IL-2) treatment in systemic lupus erythematosus (SLE) complicated with cytomegalovirus (CMV) viremia.
- Trial name
- NCT06971913
- Testing
- Interleukin-2 (IL-2), Ganciclovir (GCV)
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Peking University People's Hospital
Systemic Lupus Erythematosus
Retrospective Medical Chart Review Study to Describe the Experience of SLE Patients Treated With Anifrolumab in the Early Access Programs.
The ERYTHRO study is a retrospective medical chart review study of patients in the AMANA and ATUc Early Access Programs (EAPs) across a number of countries, to assess anifrolumab usage and patient experience in treating SLE in a…
- Trial name
- ERYTHRO (NCT06046534)
- Testing
- None (Observational study)
- Where
- 15 sites in France, Greece and 5 more
- Volunteers
- 46 people
- Sponsor
- AstraZeneca
Cutaneous Lupus Erythematosus (CLE)
Lenalidomide vs Methotrexate in Difficult-to-treat Cutaneous Lupus Erythematosus
Cutaneous lupus erythematosus (CLE) is a heterogeneous inflammatory autoimmune disease associated or not with systemic lupus erythematosus (SLE).
- Trial name
- LEISURE (NCT06965244)
- Testing
- Lenalidomide, Methotrexate (MTX)
- Volunteers
- 122 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
SLE (Systemic Lupus)
Evaluation of Patients With Lupus Nephritis Using Kidney MRI (Magnetic Resonance Imaging)
This study is being done to find out if a non-invasive Magnetic Resonance Imaging (MRI) examination of the kidneys may be helpful in patients with systemic lupus erythematosus (SLE).
- Trial name
- NCT06445127
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Johns Hopkins University
Systemic Lupus Erythematosus
A Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants With Moderately to Severely Active Systemic Lupus Erythematosus
The purpose of this study is to evaluate the ability of dapirolizumab pegol (DZP) as an add-on treatment to standard of care (SOC) medication to achieve clinically relevant long term improvement of moderate to severe disease…
- Trial name
- PHOENYCS GO (NCT04294667)
- Testing
- DZP
- Where
- 177 sites in United States, Argentina and 23 more
- Volunteers
- 321 people
- Sponsor
- UCB Biopharma SRL
Systemic Lupus Erythematosus
UCAR T-cell Therapy Targeting CD19/BCMA in Patients With r/r Systemic Lupus Erythematosus
This is an open label, single-site, dose-escalation study in up to 18 participants with relapsed or refractory Systemic lupus erythematosus.
- Trial name
- NCT06920433
- Testing
- UCAR T-cell group
- Where
- China
- Volunteers
- 18 people
- Sponsor
- Zhejiang University
Lupus Erythematosus, Systemic
A Study of Ustekinumab in Participants With Active Systemic Lupus Erythematosus
The purpose of this study is to evaluate the efficacy of ustekinumab in participants with active systemic lupus erythematosus (SLE) who have not adequately responded to one or more standard of care treatments.
- Trial name
- NCT03517722
- Testing
- Ustekinumab (approximately 6 mg/kg), Ustekinumab 90 mg
- Where
- 204 sites in United States, Argentina and 18 more
- Volunteers
- 516 people
- Sponsor
- Janssen Research & Development, LLC
Systemic Lupus Erythematosus
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneously Administered Mosunetuzumab to Participants With Systemic Lupus Erythematosus
This study will evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of mosunetuzumab in participants with systemic lupus erythematosus (SLE).
- Trial name
- NCT05155345
- Testing
- Mosunetuzumab, Tocilizumab
- Where
- 3 sites in United States, Moldova and 1 more
- Volunteers
- 15 people
- Sponsor
- Hoffmann-La Roche
Systemic Lupus Erythematosus (SLE)
An Exploratory Clinical Study of Anti-CD19 CAR NK Cells in the Treatment of Systemic Lupus Erythematosus
A single arm, open-label pilot study is designed to determine the safety and effectiveness of anti-cluster of differentiation antigen 19 (CD19) chimeric antigen receptor (CAR) natural killer (NK) cells (KN5501) in patients with…
- Trial name
- NCT06010472
- Testing
- anti-CD19 CAR NK cells (KN5501)
- Where
- China
- Volunteers
- 36 people
- Sponsor
- Changhai Hospital